NCT01518309View on ClinicalTrials.gov

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 17, 2004

Primary Completion Date

May 2, 2013

Study Completion Date

May 2, 2013

Conditions
Parkinson's Disease Psychosis
Interventions
DRUG

pimavanserin tartrate (ACP-103)

Tablets taken once daily by mouth at 20, 40, or 60 mg doses

Trial Locations (1)

06810

Danbury

Sponsors
All Listed Sponsors
lead

ACADIA Pharmaceuticals Inc.

INDUSTRY